Louise Rodino-Klapac - 01 Mar 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol
SRPT
Transactions as of
01 Mar 2023
Net transactions value
-$77,032
Form type
4
Filing time
03 Mar 2023, 19:00:38 UTC
Previous filing
21 Nov 2022
Next filing
08 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability $77,032 -522 -0.76% $147.57 67,716 01 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.
F2 Amount of Securities Beneficially Owned includes 240 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2023.